A 1 week IGF-1 infusion decreases arterial insulin concentrations but increases pancreatic insulin content and islet vascularity in fetal sheep

Alicia White, Samantha Louey, Eileen I. Chang, Brit H. Boehmer, David Goldstrohm, Sonnet Jonker, Paul J. Rozance

    Research output: Contribution to journalArticle

    Abstract

    Fetal insulin is critical for regulation of growth. Insulin concentrations are partly determined by the amount of β-cells present and their insulin content. Insulin-like growth factor-1 (IGF-1) is a fetal anabolic growth factor which also impacts β-cell mass in models of β-cell injury and diabetes. The extent to which circulating concentrations of IGF-1 impact fetal β-cell mass and pancreatic insulin content is unknown. We hypothesized that an infusion of an IGF-1 analog for 1 week into the late gestation fetal sheep circulation would increase β-cell mass, pancreatic islet size, and pancreatic insulin content. After the 1-week infusion, pancreatic insulin concentrations were 80% higher than control fetuses (P < 0.05), but there were no differences in β-cell area, β-cell mass, or pancreatic vascularity. However, pancreatic islet vascularity was 15% higher in IGF-1 fetuses and pancreatic VEGFA, HGF, IGF1, and IGF2 mRNA expressions were 70–90% higher in IGF-1 fetuses compared to control fetuses (P < 0.05). Plasma oxygen, glucose, and insulin concentrations were 25%, 22%, and 84% lower in IGF-1 fetuses, respectively (P < 0.05). The previously described role for IGF-1 as a β-cell growth factor may be more relevant for local paracrine signaling in the pancreas compared to circulating endocrine signaling.

    LanguageEnglish (US)
    Article numbere13840
    JournalPhysiological Reports
    Volume6
    Issue number17
    DOIs
    StatePublished - Sep 1 2018

    Fingerprint

    Somatomedins
    Sheep
    Insulin
    Fetus
    Islets of Langerhans
    Intercellular Signaling Peptides and Proteins
    Paracrine Communication
    Insulin-Secreting Cells
    Fetal Development
    Pancreas
    Oxygen
    Glucose
    Pregnancy
    Messenger RNA
    Wounds and Injuries
    Growth

    Keywords

    • Beta-cell
    • fetus
    • insulin
    • insulin-like growth factor
    • islet

    ASJC Scopus subject areas

    • Physiology
    • Physiology (medical)

    Cite this

    A 1 week IGF-1 infusion decreases arterial insulin concentrations but increases pancreatic insulin content and islet vascularity in fetal sheep. / White, Alicia; Louey, Samantha; Chang, Eileen I.; Boehmer, Brit H.; Goldstrohm, David; Jonker, Sonnet; Rozance, Paul J.

    In: Physiological Reports, Vol. 6, No. 17, e13840, 01.09.2018.

    Research output: Contribution to journalArticle

    @article{149df4fd1b9c40f2b59990c4e6aaafab,
    title = "A 1 week IGF-1 infusion decreases arterial insulin concentrations but increases pancreatic insulin content and islet vascularity in fetal sheep",
    abstract = "Fetal insulin is critical for regulation of growth. Insulin concentrations are partly determined by the amount of β-cells present and their insulin content. Insulin-like growth factor-1 (IGF-1) is a fetal anabolic growth factor which also impacts β-cell mass in models of β-cell injury and diabetes. The extent to which circulating concentrations of IGF-1 impact fetal β-cell mass and pancreatic insulin content is unknown. We hypothesized that an infusion of an IGF-1 analog for 1 week into the late gestation fetal sheep circulation would increase β-cell mass, pancreatic islet size, and pancreatic insulin content. After the 1-week infusion, pancreatic insulin concentrations were 80{\%} higher than control fetuses (P < 0.05), but there were no differences in β-cell area, β-cell mass, or pancreatic vascularity. However, pancreatic islet vascularity was 15{\%} higher in IGF-1 fetuses and pancreatic VEGFA, HGF, IGF1, and IGF2 mRNA expressions were 70–90{\%} higher in IGF-1 fetuses compared to control fetuses (P < 0.05). Plasma oxygen, glucose, and insulin concentrations were 25{\%}, 22{\%}, and 84{\%} lower in IGF-1 fetuses, respectively (P < 0.05). The previously described role for IGF-1 as a β-cell growth factor may be more relevant for local paracrine signaling in the pancreas compared to circulating endocrine signaling.",
    keywords = "Beta-cell, fetus, insulin, insulin-like growth factor, islet",
    author = "Alicia White and Samantha Louey and Chang, {Eileen I.} and Boehmer, {Brit H.} and David Goldstrohm and Sonnet Jonker and Rozance, {Paul J.}",
    year = "2018",
    month = "9",
    day = "1",
    doi = "10.14814/phy2.13840",
    language = "English (US)",
    volume = "6",
    journal = "Physiological Reports",
    issn = "2051-817X",
    publisher = "John Wiley and Sons Inc.",
    number = "17",

    }

    TY - JOUR

    T1 - A 1 week IGF-1 infusion decreases arterial insulin concentrations but increases pancreatic insulin content and islet vascularity in fetal sheep

    AU - White, Alicia

    AU - Louey, Samantha

    AU - Chang, Eileen I.

    AU - Boehmer, Brit H.

    AU - Goldstrohm, David

    AU - Jonker, Sonnet

    AU - Rozance, Paul J.

    PY - 2018/9/1

    Y1 - 2018/9/1

    N2 - Fetal insulin is critical for regulation of growth. Insulin concentrations are partly determined by the amount of β-cells present and their insulin content. Insulin-like growth factor-1 (IGF-1) is a fetal anabolic growth factor which also impacts β-cell mass in models of β-cell injury and diabetes. The extent to which circulating concentrations of IGF-1 impact fetal β-cell mass and pancreatic insulin content is unknown. We hypothesized that an infusion of an IGF-1 analog for 1 week into the late gestation fetal sheep circulation would increase β-cell mass, pancreatic islet size, and pancreatic insulin content. After the 1-week infusion, pancreatic insulin concentrations were 80% higher than control fetuses (P < 0.05), but there were no differences in β-cell area, β-cell mass, or pancreatic vascularity. However, pancreatic islet vascularity was 15% higher in IGF-1 fetuses and pancreatic VEGFA, HGF, IGF1, and IGF2 mRNA expressions were 70–90% higher in IGF-1 fetuses compared to control fetuses (P < 0.05). Plasma oxygen, glucose, and insulin concentrations were 25%, 22%, and 84% lower in IGF-1 fetuses, respectively (P < 0.05). The previously described role for IGF-1 as a β-cell growth factor may be more relevant for local paracrine signaling in the pancreas compared to circulating endocrine signaling.

    AB - Fetal insulin is critical for regulation of growth. Insulin concentrations are partly determined by the amount of β-cells present and their insulin content. Insulin-like growth factor-1 (IGF-1) is a fetal anabolic growth factor which also impacts β-cell mass in models of β-cell injury and diabetes. The extent to which circulating concentrations of IGF-1 impact fetal β-cell mass and pancreatic insulin content is unknown. We hypothesized that an infusion of an IGF-1 analog for 1 week into the late gestation fetal sheep circulation would increase β-cell mass, pancreatic islet size, and pancreatic insulin content. After the 1-week infusion, pancreatic insulin concentrations were 80% higher than control fetuses (P < 0.05), but there were no differences in β-cell area, β-cell mass, or pancreatic vascularity. However, pancreatic islet vascularity was 15% higher in IGF-1 fetuses and pancreatic VEGFA, HGF, IGF1, and IGF2 mRNA expressions were 70–90% higher in IGF-1 fetuses compared to control fetuses (P < 0.05). Plasma oxygen, glucose, and insulin concentrations were 25%, 22%, and 84% lower in IGF-1 fetuses, respectively (P < 0.05). The previously described role for IGF-1 as a β-cell growth factor may be more relevant for local paracrine signaling in the pancreas compared to circulating endocrine signaling.

    KW - Beta-cell

    KW - fetus

    KW - insulin

    KW - insulin-like growth factor

    KW - islet

    UR - http://www.scopus.com/inward/record.url?scp=85053300760&partnerID=8YFLogxK

    UR - http://www.scopus.com/inward/citedby.url?scp=85053300760&partnerID=8YFLogxK

    U2 - 10.14814/phy2.13840

    DO - 10.14814/phy2.13840

    M3 - Article

    VL - 6

    JO - Physiological Reports

    T2 - Physiological Reports

    JF - Physiological Reports

    SN - 2051-817X

    IS - 17

    M1 - e13840

    ER -